¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

Çѱ¹À¯¹æ¾ÏÇÐȸ Á¦18ȸ Ç׾Ͽä¹ý ½ÉÆ÷Áö¾ö : 2022-03-26

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
Çѱ¹À¯¹æ¾ÏÇÐȸ Á¦18ȸ Ç׾Ͽä¹ý ½ÉÆ÷Áö¾ö : 2022-03-26
±³À°ÀÏÀÚ : 2022-03-26
±³À°Àå¼Ò : ¼­¿ïµå·¡°ï½ÃƼ 5Ãþ ±×·£µåº¼·ë ¹éµÎȦ  
±³À°ÁÖÁ¦ : Á¦18ȸ Ç׾Ͽä¹ý ½ÉÆ÷Áö¾ö
ÁÖÃÖ±â°ü : Çѱ¹À¯¹æ¾ÏÇÐȸ
´ã´çÀÚ : Á¤Áö¿µ
¿¬¶ôó : 02-3461-6060  
À̸ÞÀÏ : kbcs@kbcs.or.kr      
±³À°Á¾·ù : ³»°ú, ¿Ü°ú      
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 5Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 15ºÐ  
¼¼ºÎ¼ö°­·á : 80,000¿ø      
ºñ°í Á¤È¸¿ø.ÁØȸ¿ø : 5¸¸¿ø / °£È£»ç.Àü°øÀÇ : 3¸¸¿ø / ºñȸ¿ø : 8¸¸¿ø / 65¼¼ÀÌ»ó : ¹«·á      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 03-26 ¹éµÎȦ 09:10~09:35 Clinical Applications of Gene Expression Signatures in HR+/HER2- Early Breast Cancer  À¯Á¾ÇÑ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 03-26 ¹éµÎȦ 09:35~10:00 Emerging Adjuvant Therapies in HR+/HER2- Early Breast Cancer : Are we ready for prime time?  ¼ÕÁÖÇõ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 03-26 ¹éµÎȦ 10:00~10:25 Systemic treatment in HR+/HER2- Metastatic Breast Cancer : Current status & Future perspectives  ÀÓ½ÂÅÃ(¿¬¼¼ÀÇ´ë) 
Åä·Ð 03-26 ¹éµÎȦ 10:25~10:35 Discussion  () 
È޽Ġ03-26  10:35~10:50 Break  () 
±³À°½Ã°£ 03-26 ¹éµÎȦ 10:50~11:15 Tailored approaches in Neoadjuvant/Adjuvant Systemic Therapy : Escalation vs. De-escalation  ¾È¼º±Í(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 03-26 ¹éµÎȦ 11:15~11:40 Optimize Metastatic HER2+ Breast Cancer with Several anti-HER2 Treatment  ¹Ú°æÈ­(°í·ÁÀÇ´ë) 
Åä·Ð 03-26 ¹éµÎȦ 11:40~11:50 Discussion  () 
½Ä»ç 03-26  11:50~12:50 Lunch  () 
±³À°½Ã°£ 03-26 ¹éµÎȦ 12:50~13:15 Recent advances in Neoadjuvant/Adjuvant Chemotherapy : Immunotherapy, Chemotherapy  ¿øÇý¼º(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 03-26 ¹éµÎȦ 13:15~13:40 Immune Checkpoint Inhibition for Metastatic TNBC : Is there an optimal combination?  À̼öÀÌ(µ¿¾ÆÀÇ´ë) 
±³À°½Ã°£ 03-26 ¹éµÎȦ 13:40~14:05 Biomarker-driven therapeutic approaches in Metastatic TNBC  Ã¤ÀǼö(°æºÏÀÇ´ë) 
Åä·Ð 03-26 ¹éµÎȦ 14:05~14:15 Discussion  () 
È޽Ġ03-26  14:15~14:30 Break  () 
±³À°½Ã°£ 03-26 ¹éµÎȦ 14:30~14:55 Breast Cancer in Pregnancy  ¹è¼ö¿¬(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 03-26 ¹éµÎȦ 14:55~15:20 Patients with Cardiac risk factors  Á¤¿ì¹é(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 03-26 ¹éµÎȦ 15:20~15:45 Systemic Treatment in Older Patients  ±èÁöÇü(¿¬¼¼ÀÇ´ë) 
Åä·Ð 03-26  15:45~15:55 Discussion  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" Çѱ¹À¯¹æ¾ÏÇÐȸ Á¦18ȸ Ç׾Ͽä¹ý ½ÉÆ÷Áö¾ö : 2022-03-26""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û (¿Â¶óÀÎ) 2022³â Á¦1Â÷ ´ëÇÑÇÙÀÇÇÐȸ Á¤µµ°ü¸® ½ÉÆ÷Áö¾ö : 2022-03-26
´ÙÀ½±Û ±¹¸³Áß¾ÓÀÇ·á¿ø °ñ´Ù°øÁõ Áø´Ü ¹× Ä¡·á¸¦ À§ÇÑ ¿öÅ©¼ó : 2022-03-26
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20897 ¼­¿ï ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ENDO 2024 (Day2) : 2024-07-05 0 124 2024-05-28
20896 ¼­¿ï ÀÓ»ó¼ú±â±³À°¿¬±¸È¸ Á¦16ȸ ÀÓ»ó¼ú±â ¿¬¼ö°­Á : 2024-07-04 0 208 2024-05-28
20895 °æ±â ¿ëÀμ¼ºê¶õ½ºº´¿ø µðÁöÅÐÀÇ·á½ÉÆ÷Áö¾ö -¹Ì·¡ ÀǷḦ À§ÇÑ ±³·ù¿Í Çù·Â : 2024-07-04 0 163 2024-05-28
20894 ¼­¿ï ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ENDO 2024 (Day1) : 2024-07-04 0 72 2024-05-28
20893 ¼­¿ï ´ëÇÑ»êºÎÀΰúÇÐȸ ¼­ºÎÁöȸ Á¤±â Áý´ãȸ(Àڱ󻸷Áõ½ÄÁõ) : 2024-07-02 0 91 2024-05-28
20892 ¼­¿ï ´ëÇѼҾƽÅÀåÇÐȸ (¿Â¶óÀÎ) 2024³â ¼Ò¾Æ½ÅÀå Post-graduate education course : 2024-07-01 0 52 2024-05-28
20891 ´ëÀü Ãæ³²´ëÇб³º´¿ø 2024³â °³¿øÀÇ¿Í ÇÔ²²ÇÏ´Â ³»°ú ¿¬¼ö°­Á : 2024-06-30 0 83 2024-05-28
20890 ¼­¿ï ´ëÇѳúÁ¹ÁßÇÐȸ 6¿ù º¸¼ö±³À° : 2024-06-30 0 183 2024-05-27
20889 ¼­¿ï (¿Â¶óÀÎ)Á¦22Â÷ ¼­¿ïƯº°½ÃÀÇ»çȸ Çмú´ëȸ : 2024-06-30 0 118 2024-05-27
20888 °æ±â (¿Â¶óÀÎ)Á¦21Â÷ °æ±âµµÀÇ»çȸ ¿Â¶óÀÎ Çмú´ëȸ : 2024-06-30 0 250 2024-05-27
20887 Àü³² 2024³â ´ëÇÑ´ëÀåÇ×¹®ÇÐȸ ¿¬¼ö°­Á : 2024-06-30 0 118 2024-05-27
20886 Ãæ³² ´ëÇÑÁ¤Çü¿Ü°úÃÊÀ½ÆÄÇÐȸ - Á¦19Â÷ Ãá°èÇмú´ëȸ ¹× Á¦38Â÷ ±Ù°ñ°Ý°è ÃÊÀ½ÆÄ¿öÅ©¼¥ (Basic Course) : 2024-06-30 0 57 2024-05-27
20885 ºÎ»ê Á¦3ȸ ´ëÇÑÅõ¼®Çùȸ ºÎ»êÁöȸ ½ÉÆ÷Áö¾ö : 2024-06-29 0 57 2024-05-27
20884 ¼­¿ï Çѱ¹ÁöÁú¤ýµ¿¸Æ°æÈ­ÇÐȸ Á¦7ȸ A to Z (Atherosclerosis to Zero) ¿¬¼ö°­Á ÇÁ·Î±×·¥ : 2024-06-29 0 98 2024-05-27
20883 °æ±â 2024³âµµ ³²¾çÁÖ½ÃÀÇ»çȸ Çмú´ëȸ : 2024-06-29 0 92 2024-05-27
21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷